risperdal 1mg
janssen-cilag gmbh (8009839) - risperidon - filmtablette - risperidon (24756) 1 milligramm
clont 400 mg
infectopharm arzneimittel und consilium gmbh (3291423) - metronidazol - filmtablette - teil 1 - filmtablette; metronidazol (01913) 400 milligramm
blopress 16 mg
cheplapharm arzneimittel gmbh (8023489) - candesartancilexetil - tablette - teil 1 - tablette; candesartancilexetil (27048) 16 milligramm
brintellix 20 mg/ml tropfen zum einnehmen, lösung
lundbeck (schweiz) ag - vortioxetinum - tropfen zum einnehmen, lösung - vortioxetinum 20 mg ut vortioxetini lactas, hydroxypropylbetadexum, ethanolum 96 per centum 85 mg, aqua purificata, q.s. ad solutionem pro 1 ml, corresp. 20 guttae corresp. ethanolum 10.1 % v/v. - antidepressivum - synthetika
revolade 25mg pulver zur herstellung einer oralen suspension
novartis pharma schweiz ag - eltrombopagum - pulver zur herstellung einer oralen suspension - eltrombopagum 25 mg ut eltrombopagum olaminum, mannitolum, sucralosum, xanthani gummi, ad pulverem pro charta. - zur behandlung von erwachsenen patienten mit (idiopathischen) immunthrombozytopenischen purpura (itp), die auf andere therapieoptionen (z.b. kortikosteroide, immunglobuline oder splenektomie) nicht genügend ansprachen, bei erhöhtem blutungsrisiko infolge ausgeprägter thrombozytopenie - synthetika
verzenios
eli lilly nederland b.v. - abemaciclib - brustgeschwulste - antineoplastische mittel - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.
tepmetko
merck europe b.v. - tepotinib hydrochloride monohydrate - karzinom, nicht kleinzellige lunge - antineoplastische mittel - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
olmetec 40 mg
daiichi sankyo europe gmbh (3043984) - olmesartanmedoxomil - filmtablette - teil 1 - filmtablette; olmesartanmedoxomil (27955) 40 milligramm
olmetec 20 mg
daiichi sankyo europe gmbh (3043984) - olmesartanmedoxomil - filmtablette - teil 1 - filmtablette; olmesartanmedoxomil (27955) 20 milligramm
olmetec 10 mg
daiichi sankyo europe gmbh (3043984) - olmesartanmedoxomil - filmtablette - teil 1 - filmtablette; olmesartanmedoxomil (27955) 10 milligramm